Amicus Therapeutics Stock Price. Everything You Need To Know About The Amicus Therapeutics Stock!
Amicus Therapeutics, Inc. is a biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company’s portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.
Amicus Therapeutics Stock Price. Everything You Need To Know About The Amicus Therapeutics Stock! performance
- Employees 484
- Company HQ PHILADELPHIA
- Website https://www.amicusrx.com/
- FOLD Asset Type Common Stock
- FOLD Market Capitalization 3B
- Earnings Per Share -0.51
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Amicus Therapeutics, a leading biotechnology company, presents an exciting investment opportunity for retail investors from Malaysia, Thailand, Indonesia, and Vietnam. As an expert at Zorion, we understand the importance of making informed investment decisions, which is why we provide valuable insights and recommendations about Amicus Therapeutics. To begin investing in Amicus Therapeutics from Malaysia, Thailand, Indonesia, and Vietnam, it is crucial to understand the company’s potential. This biotechnology firm specializes in developing innovative therapies for rare genetic diseases. With a diversified pipeline and a commitment to transforming patients’ lives, Amicus Therapeutics presents a promising investment prospect. To invest in Amicus Therapeutics confidently, retail investors in Malaysia, Thailand, Indonesia, and Vietnam can take advantage of the resources and educational materials provided by Zorion. Our platform offers comprehensive information, analysis, and investment strategies to empower investors to make prudent choices. By staying informed about Amicus Therapeutics’ latest developments, clinical trials, and market trends, retail investors can capitalize on potential growth opportunities. Zorion connects investors from Malaysia, Thailand, Indonesia, and Vietnam to the exciting world of biotech investing, helping them make informed decisions and maximize their investment potential. Begin your journey into biotechnology investing with Amicus Therapeutics today.
